ARTICLE | Distillery Therapeutics
Cancer
September 11, 2017 7:27 PM UTC
Mouse studies suggest EP300 inhibition with doxorubicin could help treat p53-mutant colorectal cancer without the anemic and neutropenic side effects of doxorubicin alone. In a xenograft mouse model o...
BCIQ Company Profiles
BCIQ Target Profiles